Lyell Immunopharma启动首例头对头CAR-T细胞疗法3期临床试验,针对侵袭性大B细胞淋巴瘤患者开始给药

美股速递
Feb 12

Lyell Immunopharma, Inc.(简称Lyell)宣布,在一项开创性的3期临床试验中,已开始对侵袭性大B细胞淋巴瘤患者进行给药。该试验采用头对头比较设计,是同类CAR-T细胞疗法中的首例研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10